Samsung Bioepis Co., Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Samsung Bioepis Co., Ltd.
With the European Commission’s approval of Aybintio (bevacizumab), Samsung Bioepis now has five approved biosimilars for Europe.
Samsung Bioepis has launched its Ontruzant rival to Herceptin in Brazil, claiming the first biosimilar trastuzumab to be supplied to the country’s public health system for early and metastatic HER2-overexpressing breast cancer.
Second-quarter earnings results from two of the Big Three – Teva and Mylan – hold much of the intrigue in August, while more competition in the nascent Avastin biosimilar market could materialize in Europe.
- Large Molecule
- Other Names / Subsidiaries
- Samsung Biologics
- Samsung Bioepis JV
- Samsung Bioepis BR Pharmaceutical LTDA